Physician profile
Aran Groves
NPI 1841794617
$2,677.82
in general payments reported to CMS, 2019-2025
10 companies · $742 in 2025
The $742 reported for 2025 was more than what 75% of Neurodevelopmental Disabilities (Pediatrics) providers received nationally (typical 2025 total: $136).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $508 · 2023: $605 · 2024: $822 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,169.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $782.17 | 2022-2025 | Epidiolex |
| Ucb, INC. | $713.55 | 2022-2025 | Fintepla, Briviact |
| Pyros Pharmaceuticals, INC. | $322.68 | 2023-2024 | Vigpoder |
| Neurelis, INC. | $240.87 | 2024-2025 | Valtoco |
| Medtronic, INC. | $171.77 | 2025 | Percept PC Brainsense |
| Immedica Pharma US, INC. | $140.23 | 2023 | |
| Biomarin Pharmaceutical INC. | $129.13 | 2022 | |
| Livanova USA, INC. | $63.93 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Acadia Pharmaceuticals INC | $60.19 | 2024 | Daybue |
| Upsher-Smith Laboratories LLC | $53.30 | 2024-2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aran Groves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.